Showing results (141-150 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|December 5, 2018
First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumorsToshihiko Doi, Kiyotaka Yoh, Kohei Shitara, et al.
Investigational New Drugs|December 5, 2018
A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancerWeihua Hou, Qingyun Yuan, Xingxing Yuan, et al.
Investigational New Drugs|January 7, 2019
Human antigen R and drug resistance in tumorsFenghai Zhou, Fa Zhang, Chuan Zhou, et al.
Investigational New Drugs|November 27, 2020
Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancerYing Wang, Zhigang Hu, Weiyuan Ma, et al.
Investigational New Drugs|December 10, 2020
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesotheliomaIrene Dell'Anno, Sarah A Martin, Marcella Barbarino, et al.
Investigational New Drugs|December 15, 2018
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancerAlexandra Leary, Christophe Le Tourneau, Andrea Varga, et al.
Investigational New Drugs|March 7, 2018
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancerLaura Graham, Kalyan Banda, Alba Torres, et al.
Investigational New Drugs|March 7, 2018
Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cellsSonglin Liu, Yunhong Tang, Xianrui Yuan, et al.
Investigational New Drugs|December 27, 2017
A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancerMuhammad Alamgeer, D Neil Watkins, Ilia Banakh, et al.
Investigational New Drugs|December 17, 2013
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancerYoon-Koo Kang, Kei Muro, Min-Hee Ryu, et al.
Pageof 372